Open Access 12-03-2025 | Original Research Article
Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA
Published in: PharmacoEconomics
Login to get accessPlease log in to get access to this content
Appendix
Available only for authorised users
Literature
1.
go back to reference Pardo de Santayana C, Tin Tin Htar M, Findlow J, Balmer P. Epidemiology of invasive meningococcal disease worldwide from 2010–2019: a literature review. Epidemiol Infect. 2023;151: e57. https://doi.org/10.1017/S0950268823000328.CrossRefPubMedPubMedCentral
Pardo de Santayana C, Tin Tin Htar M, Findlow J, Balmer P. Epidemiology of invasive meningococcal disease worldwide from 2010–2019: a literature review. Epidemiol Infect. 2023;151: e57. https://doi.org/10.1017/S0950268823000328.CrossRefPubMedPubMedCentral
2.
go back to reference Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–98. https://doi.org/10.1016/j.jinf.2020.05.079.CrossRefPubMed
Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–98. https://doi.org/10.1016/j.jinf.2020.05.079.CrossRefPubMed
3.
go back to reference CDC. Meningococcal disease surveillance: Centres for Disease Control and Prevention; 2023. Available from: https://www.cdc.gov/meningococcal/php/surveillance/?CDC_AAref_Val=https://www.cdc.gov/meningococcal/surveillance/index.html. Accessed 14 Nov 2023.
CDC. Meningococcal disease surveillance: Centres for Disease Control and Prevention; 2023. Available from: https://www.cdc.gov/meningococcal/php/surveillance/?CDC_AAref_Val=https://www.cdc.gov/meningococcal/surveillance/index.html. Accessed 14 Nov 2023.
4.
go back to reference CDC. Enhanced meningococcal disease surveillance report; 2022. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2022-508.pdf. (Accessed 9 Feb 2024).
CDC. Enhanced meningococcal disease surveillance report; 2022. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2022-508.pdf. (Accessed 9 Feb 2024).
5.
go back to reference Mbaeyi S, Duffy J, McNamara LA. Meningococcal disease. In: CDC. The Pink Book. Washington, D.C.: Public Health Foundation; 2021.
Mbaeyi S, Duffy J, McNamara LA. Meningococcal disease. In: CDC. The Pink Book. Washington, D.C.: Public Health Foundation; 2021.
6.
go back to reference Shen J, Begum N, Ruiz-Garcia Y, Martinon-Torres F, Bekkat-Berkani R, Meszaros K. Range of invasive meningococcal disease sequelae and health economic application: a systematic and clinical review. BMC Public Health. 2022;22(1):1078. https://doi.org/10.1186/s12889-022-13342-2.CrossRefPubMedPubMedCentral
Shen J, Begum N, Ruiz-Garcia Y, Martinon-Torres F, Bekkat-Berkani R, Meszaros K. Range of invasive meningococcal disease sequelae and health economic application: a systematic and clinical review. BMC Public Health. 2022;22(1):1078. https://doi.org/10.1186/s12889-022-13342-2.CrossRefPubMedPubMedCentral
7.
go back to reference Shen J, Bouée S, Aris E, Emery C, Beck EC. Long-term mortality and state financial support in invasive meningococcal disease: real-world data analysis using the French National Claims Database (SNIIRAM). Infect Dis Ther. 2022;11(1):249–62. https://doi.org/10.1007/s40121-021-00546-z.CrossRefPubMed
Shen J, Bouée S, Aris E, Emery C, Beck EC. Long-term mortality and state financial support in invasive meningococcal disease: real-world data analysis using the French National Claims Database (SNIIRAM). Infect Dis Ther. 2022;11(1):249–62. https://doi.org/10.1007/s40121-021-00546-z.CrossRefPubMed
8.
go back to reference Clark LJ, Glennie L, Audrey S, Hickman M, Trotter CL. The health, social and educational needs of children who have survived meningitis and septicaemia: the parents’ perspective. BMC Public Health. 2013;13:954. https://doi.org/10.1186/1471-2458-13-954.CrossRefPubMedPubMedCentral
Clark LJ, Glennie L, Audrey S, Hickman M, Trotter CL. The health, social and educational needs of children who have survived meningitis and septicaemia: the parents’ perspective. BMC Public Health. 2013;13:954. https://doi.org/10.1186/1471-2458-13-954.CrossRefPubMedPubMedCentral
9.
go back to reference WHO. Meningitis: World Health Organization; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/meningitis. Accessed 22 Nov 2023.
WHO. Meningitis: World Health Organization; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/meningitis. Accessed 22 Nov 2023.
10.
go back to reference Herrera-Restrepo O, Afroz N, Cabrera ES, Reaney M, Sowell FG, Kumar R, et al. Initial experiences with invasive meningococcal disease: insights from survivors and their caregivers. Infect Dis Ther. 2024;13(12):2581–95.CrossRefPubMedPubMedCentral
Herrera-Restrepo O, Afroz N, Cabrera ES, Reaney M, Sowell FG, Kumar R, et al. Initial experiences with invasive meningococcal disease: insights from survivors and their caregivers. Infect Dis Ther. 2024;13(12):2581–95.CrossRefPubMedPubMedCentral
11.
go back to reference Herrera-Restrepo O, Afroz N, Cabrera ES, Reaney M, Sowell FG, Kumar R, et al. Life after invasive meningococcal disease: insights from survivors and their caregivers. Infect Dis Ther. 2024;13(12):2563–79.CrossRefPubMedPubMedCentral
Herrera-Restrepo O, Afroz N, Cabrera ES, Reaney M, Sowell FG, Kumar R, et al. Life after invasive meningococcal disease: insights from survivors and their caregivers. Infect Dis Ther. 2024;13(12):2563–79.CrossRefPubMedPubMedCentral
12.
go back to reference Olbrich KJ, Müller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–38. https://doi.org/10.1007/s40121-018-0213-2.CrossRefPubMedPubMedCentral
Olbrich KJ, Müller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–38. https://doi.org/10.1007/s40121-018-0213-2.CrossRefPubMedPubMedCentral
13.
go back to reference CDC. Advisory Committee on Immunization Practices summary report October 27–28, 2010. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm. Accessed 9 Feb 2024.
CDC. Advisory Committee on Immunization Practices summary report October 27–28, 2010. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm. Accessed 9 Feb 2024.
14.
go back to reference CDC. Advisory Committee on Immunization Practices summary report June 26–27, 2019. Available from: https://stacks.cdc.gov/view/cdc/82365. Accessed 9 Feb 2024.
CDC. Advisory Committee on Immunization Practices summary report June 26–27, 2019. Available from: https://stacks.cdc.gov/view/cdc/82365. Accessed 9 Feb 2024.
15.
go back to reference CDC. Meningococcal vaccine recommendations; 2023. Available from: https://www.cdc.gov/vaccines/vpd/mening/hcp/recommendations.html. Accessed 9 Feb 2024.
CDC. Meningococcal vaccine recommendations; 2023. Available from: https://www.cdc.gov/vaccines/vpd/mening/hcp/recommendations.html. Accessed 9 Feb 2024.
16.
go back to reference Niccolai LM, Hansen CE. Suboptimal uptake of meningococcal vaccines among older adolescents: barriers, solutions, and future research directions. Hum Vaccin Immunother. 2020;16(12):3208–12. https://doi.org/10.1080/21645515.2020.1754052.CrossRefPubMedPubMedCentral
Niccolai LM, Hansen CE. Suboptimal uptake of meningococcal vaccines among older adolescents: barriers, solutions, and future research directions. Hum Vaccin Immunother. 2020;16(12):3208–12. https://doi.org/10.1080/21645515.2020.1754052.CrossRefPubMedPubMedCentral
17.
go back to reference Schillie S. Revising the adolescent meningococcal vaccine schedule: term of reference and considerations. National Center for Immunization & Respiratory Diseases; 2024. Available from: https://stacks.cdc.gov/view/cdc/148680. Accessed 29 Feb 2024.
Schillie S. Revising the adolescent meningococcal vaccine schedule: term of reference and considerations. National Center for Immunization & Respiratory Diseases; 2024. Available from: https://stacks.cdc.gov/view/cdc/148680. Accessed 29 Feb 2024.
18.
go back to reference Jiang S, Wang Y, Si L, Zang X, Gu YY, Jiang Y, et al. Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China. BMJ Glob Health. 2022;7(8):e009777. https://doi.org/10.1136/bmjgh-2022-009777.CrossRefPubMedPubMedCentral
Jiang S, Wang Y, Si L, Zang X, Gu YY, Jiang Y, et al. Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China. BMJ Glob Health. 2022;7(8):e009777. https://doi.org/10.1136/bmjgh-2022-009777.CrossRefPubMedPubMedCentral
19.
go back to reference Wang B, Santoreneos R, Afzali H, Giles L, Marshall H. Costs of invasive meningococcal disease: a global systematic review. Pharmacoeconomics. 2018;36(10):1201–22. https://doi.org/10.1007/s40273-018-0679-5.CrossRefPubMed
Wang B, Santoreneos R, Afzali H, Giles L, Marshall H. Costs of invasive meningococcal disease: a global systematic review. Pharmacoeconomics. 2018;36(10):1201–22. https://doi.org/10.1007/s40273-018-0679-5.CrossRefPubMed
20.
go back to reference Scholz S, Koerber F, Meszaros K, Fassbender RM, Ultsch B, Welte RR, et al. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine. 2019;37(12):1692–701. https://doi.org/10.1016/j.vaccine.2019.01.013.CrossRefPubMed
Scholz S, Koerber F, Meszaros K, Fassbender RM, Ultsch B, Welte RR, et al. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine. 2019;37(12):1692–701. https://doi.org/10.1016/j.vaccine.2019.01.013.CrossRefPubMed
21.
go back to reference Taha MK, Martinon-Torres F, Köllges R, Bonanni P, Safadi MAP, Booy R, et al. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Rev Vaccines. 2022;21(5):659–74.CrossRefPubMed
Taha MK, Martinon-Torres F, Köllges R, Bonanni P, Safadi MAP, Booy R, et al. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Rev Vaccines. 2022;21(5):659–74.CrossRefPubMed
22.
go back to reference Stawasz A, Huang L, Kirby P, Bloom D. Health technology assessment for vaccines against rare, severe infections: properly accounting for serogroup B meningococcal vaccination’s full social and economic benefits. Front Public Health. 2020;8:261. https://doi.org/10.3389/fpubh.2020.00261.CrossRefPubMedPubMedCentral
Stawasz A, Huang L, Kirby P, Bloom D. Health technology assessment for vaccines against rare, severe infections: properly accounting for serogroup B meningococcal vaccination’s full social and economic benefits. Front Public Health. 2020;8:261. https://doi.org/10.3389/fpubh.2020.00261.CrossRefPubMedPubMedCentral
23.
go back to reference Postma M, Biundo E, Chicoye A, Devlin N, Mark Doherty T, Garcia-Ruiz AJ, et al. Capturing the value of vaccination within health technology assessment and health economics: country analysis and priority value concepts. Vaccine. 2022;40(30):3999–4007. https://doi.org/10.1016/j.vaccine.2022.04.026.CrossRefPubMed
Postma M, Biundo E, Chicoye A, Devlin N, Mark Doherty T, Garcia-Ruiz AJ, et al. Capturing the value of vaccination within health technology assessment and health economics: country analysis and priority value concepts. Vaccine. 2022;40(30):3999–4007. https://doi.org/10.1016/j.vaccine.2022.04.026.CrossRefPubMed
24.
go back to reference Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115(5):1220–32. https://doi.org/10.1542/peds.2004-2514.CrossRefPubMed
Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115(5):1220–32. https://doi.org/10.1542/peds.2004-2514.CrossRefPubMed
25.
go back to reference Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008;46(1):1–13. https://doi.org/10.1086/524041.CrossRefPubMed
Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. 2008;46(1):1–13. https://doi.org/10.1086/524041.CrossRefPubMed
26.
go back to reference Leeds IL, Namasivayam V, Bamogo A, Sankhla P, Thayer WM. Cost effectiveness of meningococcal serogroup B vaccination in college-aged young adults. Am J Prev Med. 2019;56(2):196–204.CrossRefPubMed
Leeds IL, Namasivayam V, Bamogo A, Sankhla P, Thayer WM. Cost effectiveness of meningococcal serogroup B vaccination in college-aged young adults. Am J Prev Med. 2019;56(2):196–204.CrossRefPubMed
27.
go back to reference Chung GS, Hutton DW. Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry. PLoS One. 2020;15(10): e0239926.CrossRefPubMedPubMedCentral
Chung GS, Hutton DW. Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry. PLoS One. 2020;15(10): e0239926.CrossRefPubMedPubMedCentral
28.
go back to reference CDC. Enhanced meningococcal disease surveillance report, 2021. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2021.pdf. Accessed 1 Apr 2024.
CDC. Enhanced meningococcal disease surveillance report, 2021. Available from: https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2021.pdf. Accessed 1 Apr 2024.
29.
go back to reference Grosse SD, Krueger KV, Pike J. Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations. J Med Econ. 2019;22(6):501–8. https://doi.org/10.1080/13696998.2018.1542520.CrossRefPubMed
Grosse SD, Krueger KV, Pike J. Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations. J Med Econ. 2019;22(6):501–8. https://doi.org/10.1080/13696998.2018.1542520.CrossRefPubMed
30.
go back to reference Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103. https://doi.org/10.1001/jama.2016.12195.CrossRefPubMed
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103. https://doi.org/10.1001/jama.2016.12195.CrossRefPubMed
31.
go back to reference U.S. Bureau of Labor Statistics. Table 3. Time spent in primary activities for the civilian population by age, sex, race, Hispanic or Latino ethnicity, marital status, and educational attainment, 2022 annual averages: U.S. Bureau of Labor Statistics; 2023. Available from: www.bls.gov/news.release/archives/atus_06222023.pdf. Accessed 9 Feb 2024.
U.S. Bureau of Labor Statistics. Table 3. Time spent in primary activities for the civilian population by age, sex, race, Hispanic or Latino ethnicity, marital status, and educational attainment, 2022 annual averages: U.S. Bureau of Labor Statistics; 2023. Available from: www.bls.gov/news.release/archives/atus_06222023.pdf. Accessed 9 Feb 2024.
32.
go back to reference Grosse SD, Krueger KV, Mvundura M. Economic productivity by age and sex: 2007 estimates for the United States. Med Care. 2009;47(7 Suppl. 1):S94-103. https://doi.org/10.1097/MLR.0b013e31819c9571.CrossRefPubMed
Grosse SD, Krueger KV, Mvundura M. Economic productivity by age and sex: 2007 estimates for the United States. Med Care. 2009;47(7 Suppl. 1):S94-103. https://doi.org/10.1097/MLR.0b013e31819c9571.CrossRefPubMed
33.
go back to reference US Bureau of Economic Analysis. Gross domestic product: implicit price deflator (GDPDEF), retrieved from FRED, Federal Reserve Bank of St. Louis; 2023. Available from: https://fred.stlouisfed.org/series/GDPDEF. Accessed 12 Mar 2024.
US Bureau of Economic Analysis. Gross domestic product: implicit price deflator (GDPDEF), retrieved from FRED, Federal Reserve Bank of St. Louis; 2023. Available from: https://fred.stlouisfed.org/series/GDPDEF. Accessed 12 Mar 2024.
34.
go back to reference Pingali C, Yankey D, Elam-Evans LD, Markowitz LE, Valier MR, Fredua B, et al. Vaccination coverage among adolescents aged 13–17 years: National Immunization Survey-Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(34):912–9. https://doi.org/10.15585/mmwr.mm7234a3.CrossRefPubMedPubMedCentral
Pingali C, Yankey D, Elam-Evans LD, Markowitz LE, Valier MR, Fredua B, et al. Vaccination coverage among adolescents aged 13–17 years: National Immunization Survey-Teen, United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(34):912–9. https://doi.org/10.15585/mmwr.mm7234a3.CrossRefPubMedPubMedCentral
35.
go back to reference CDC. Revising the adolescent meningococcal vaccine schedule: term of reference and considerations; 2024. Available from: https://stacks.cdc.gov/view/cdc/148680. Accessed 12 Mar 2024.
CDC. Revising the adolescent meningococcal vaccine schedule: term of reference and considerations; 2024. Available from: https://stacks.cdc.gov/view/cdc/148680. Accessed 12 Mar 2024.
36.
go back to reference U.S. Department of Labor. Workers under 18; 2024. Available from: https://www.dol.gov/general/topic/hiring/workersunder18#:~:text=Generally%20speaking%2C%20the%20Fair%20Labor,being%20employed%20in%20hazardous%20occupations. Accessed 7 Mar 2024.
U.S. Department of Labor. Workers under 18; 2024. Available from: https://www.dol.gov/general/topic/hiring/workersunder18#:~:text=Generally%20speaking%2C%20the%20Fair%20Labor,being%20employed%20in%20hazardous%20occupations. Accessed 7 Mar 2024.
37.
go back to reference MacNeil JR, Blain AE, Wang X, Cohn AC. Current epidemiology and trends in meningococcal disease-United States, 1996–2015. Clin Infect Dis. 2018;66(8):1276–81. https://doi.org/10.1093/cid/cix993.CrossRefPubMed
MacNeil JR, Blain AE, Wang X, Cohn AC. Current epidemiology and trends in meningococcal disease-United States, 1996–2015. Clin Infect Dis. 2018;66(8):1276–81. https://doi.org/10.1093/cid/cix993.CrossRefPubMed
38.
go back to reference CDC. Enhanced meningococcal disease surveillance report; 2021. Available from: www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2021.pdf. Accessed 9 Feb 2024.
CDC. Enhanced meningococcal disease surveillance report; 2021. Available from: www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2021.pdf. Accessed 9 Feb 2024.
39.
go back to reference Healthcare Cost and Utilization Project (HCUPnet). 2020 dataset. Available from: https://datatools.ahrq.gov/hcupnet/. Accessed 11 Feb 2025.
Healthcare Cost and Utilization Project (HCUPnet). 2020 dataset. Available from: https://datatools.ahrq.gov/hcupnet/. Accessed 11 Feb 2025.
40.
go back to reference Arias E, Xu J. United States life tables, 2019. Available from: https://stacks.cdc.gov/view/cdc/113096. Accessed 5 Apr 2024.
Arias E, Xu J. United States life tables, 2019. Available from: https://stacks.cdc.gov/view/cdc/113096. Accessed 5 Apr 2024.
41.
go back to reference Rissanen I, Ala-Mursula L, Nerg I, Korhonen M. Adjusted productivity costs of stroke by human capital and friction cost methods: a Northern Finland Birth Cohort 1966 study. Eur J Health Econ. 2021;22(4):531–45. https://doi.org/10.1007/s10198-021-01271-7.CrossRefPubMedPubMedCentral
Rissanen I, Ala-Mursula L, Nerg I, Korhonen M. Adjusted productivity costs of stroke by human capital and friction cost methods: a Northern Finland Birth Cohort 1966 study. Eur J Health Econ. 2021;22(4):531–45. https://doi.org/10.1007/s10198-021-01271-7.CrossRefPubMedPubMedCentral
42.
go back to reference Rojanasarot S, Bhattacharyya SK, Edwards N. Productivity loss and productivity loss costs to United States employers due to priority conditions: a systematic review. J Med Econ. 2023;26(1):262–70. https://doi.org/10.1080/13696998.2023.2172282.CrossRefPubMed
Rojanasarot S, Bhattacharyya SK, Edwards N. Productivity loss and productivity loss costs to United States employers due to priority conditions: a systematic review. J Med Econ. 2023;26(1):262–70. https://doi.org/10.1080/13696998.2023.2172282.CrossRefPubMed
43.
go back to reference Marshall GS, McCormick ZL, Johns JS, Verduzco-Gutierrez M, Herrera-Restrepo O, Harrison LH. Understanding the sequelae of invasive meningococcal disease in the United States. Infect Dis Ther. 2024;13(11):2213–20.CrossRefPubMedPubMedCentral
Marshall GS, McCormick ZL, Johns JS, Verduzco-Gutierrez M, Herrera-Restrepo O, Harrison LH. Understanding the sequelae of invasive meningococcal disease in the United States. Infect Dis Ther. 2024;13(11):2213–20.CrossRefPubMedPubMedCentral
44.
go back to reference U.S. Bureau of Labor Statistics. Usual weekly earnings of wage and salary workers. News release. 2023.
U.S. Bureau of Labor Statistics. Usual weekly earnings of wage and salary workers. News release. 2023.
45.
go back to reference Davis KL, Misurski D, Miller J, Karve S. Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Hum Vaccin. 2011;7(4):458–65. https://doi.org/10.4161/hv.7.4.14434.CrossRefPubMed
Davis KL, Misurski D, Miller J, Karve S. Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Hum Vaccin. 2011;7(4):458–65. https://doi.org/10.4161/hv.7.4.14434.CrossRefPubMed
46.
go back to reference U.S. Bureau of Labor Statistics. Costs for employee compensation: December 2023. 2024. Available from: https://www.bls.gov/news.release/archives/ecec_03132024.pdf. Accessed 12 Aug 2024.
U.S. Bureau of Labor Statistics. Costs for employee compensation: December 2023. 2024. Available from: https://www.bls.gov/news.release/archives/ecec_03132024.pdf. Accessed 12 Aug 2024.
47.
go back to reference Pike J, Grosse SD. Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review. Appl Health Econ Health Policy. 2018;16(6):765–78. https://doi.org/10.1007/s40258-018-0416-4.CrossRefPubMedPubMedCentral
Pike J, Grosse SD. Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review. Appl Health Econ Health Policy. 2018;16(6):765–78. https://doi.org/10.1007/s40258-018-0416-4.CrossRefPubMedPubMedCentral
48.
go back to reference Lambert TE. The great resignation in the United States: a study of labor market segmentation. Forum Soc Econ. 2023;52(4):373–86. https://doi.org/10.1080/07360932.2022.2164599.CrossRef
Lambert TE. The great resignation in the United States: a study of labor market segmentation. Forum Soc Econ. 2023;52(4):373–86. https://doi.org/10.1080/07360932.2022.2164599.CrossRef
49.
go back to reference Zeevat F, Simons JJM, Westra TA, Wilschut JC, van Sorge NM, Boersma C, et al. Cost of illness analysis of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in the Netherlands: a holistic approach. Infect Dis Ther. 2024;13(3):481–99. https://doi.org/10.1007/s40121-023-00903-0.CrossRefPubMedPubMedCentral
Zeevat F, Simons JJM, Westra TA, Wilschut JC, van Sorge NM, Boersma C, et al. Cost of illness analysis of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in the Netherlands: a holistic approach. Infect Dis Ther. 2024;13(3):481–99. https://doi.org/10.1007/s40121-023-00903-0.CrossRefPubMedPubMedCentral
50.
go back to reference CDC. Meningococcal vaccination for adolescents: information for healthcare professionals. 2023. Available from: https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/?CDC_AAref_Val=https://www.cdc.gov/vaccines/vpd/mening/hcp/adolescent-vaccine.html. Accessed 9 Feb 2024.
CDC. Meningococcal vaccination for adolescents: information for healthcare professionals. 2023. Available from: https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/?CDC_AAref_Val=https://www.cdc.gov/vaccines/vpd/mening/hcp/adolescent-vaccine.html. Accessed 9 Feb 2024.
51.
go back to reference Begum S, Cabrera ES, Herrera-Restrepo O, Khera T, Botha W, Batchelder L, et al. 1150. Invasive meningococcal disease vaccination: a targeted literature review of adolescents and parents/caregivers’ preferences. Open Forum Infect Dis. 2023;10(Suppl 2):S509. https://doi.org/10.1093/ofid/ofad500.991.CrossRef
Begum S, Cabrera ES, Herrera-Restrepo O, Khera T, Botha W, Batchelder L, et al. 1150. Invasive meningococcal disease vaccination: a targeted literature review of adolescents and parents/caregivers’ preferences. Open Forum Infect Dis. 2023;10(Suppl 2):S509. https://doi.org/10.1093/ofid/ofad500.991.CrossRef
52.
go back to reference Begum S, Cabrera ES, Hortobagyi L, Khera T, Correa SC, Batchelder L, et al. 1137. The value of invasive meningococcal disease combination vaccine: a qualitative study of adolescents and parents/caregivers’ preferences in the US. Open Forum Infect Dis. 2023;10(Suppl 2):S509. https://doi.org/10.1093/ofid/ofad500.978.CrossRefPubMedCentral
Begum S, Cabrera ES, Hortobagyi L, Khera T, Correa SC, Batchelder L, et al. 1137. The value of invasive meningococcal disease combination vaccine: a qualitative study of adolescents and parents/caregivers’ preferences in the US. Open Forum Infect Dis. 2023;10(Suppl 2):S509. https://doi.org/10.1093/ofid/ofad500.978.CrossRefPubMedCentral
53.
go back to reference Church JD. Comparing the Consumer Price Index with the gross domestic product price index and gross domestic product implicit price deflator: U.S. Bureau of Labor Statistics; 2016. Available from: https://www.bls.gov/opub/mlr/2016/article/comparing-the-cpi-with-the-gdp-price-index-and-gdp-implicit-price-deflator.htm. Accessed 19 Dec 2023.
Church JD. Comparing the Consumer Price Index with the gross domestic product price index and gross domestic product implicit price deflator: U.S. Bureau of Labor Statistics; 2016. Available from: https://www.bls.gov/opub/mlr/2016/article/comparing-the-cpi-with-the-gdp-price-index-and-gdp-implicit-price-deflator.htm. Accessed 19 Dec 2023.
Metadata
- Title
- Market and Non-Market Productivity Losses Associated with Invasive Meningococcal Disease in the USA
- Authors
-
Hiral Anil Shah
Ginita Jutlla
Oscar Herrera-Restrepo
Jonathan Graham
Mei Grace
Shah Alam Khan
Elise Kuylen
Shahina Begum
Frederik Verelst
Zeki Kocaata
- Publication date
- 12-03-2025
- Publisher
- Springer International Publishing
- Published in
-
PharmacoEconomics
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027 - DOI
- https://doi.org/10.1007/s40273-025-01477-0